10X Genomics, Inc. current report, 12 February 2020

Full document

10x Genomics, Inc. Form 8-K Summary

Business context and reporting period

10x Genomics filed a Current Report on Form 8-K dated February 12, 2020, under Item 7.01, Regulation FD Disclosure. The filing concerns the International Trade Commission (ITC) proceeding against Bio-Rad Laboratories, Inc. regarding alleged infringement of 10x Genomics patents by Bio-Rad’s ddSEQ products.

Key financial metrics

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other quantitative financial metrics. It is not a results or periodic financial report.

Material developments

  • On February 12, 2020, the ITC issued a Final Determination affirming that Bio-Rad violated 10x Genomics’ U.S. Patent Nos. 9,689,024, 9,695,468, and 9,856,530.
  • The ITC affirmed findings that the patents were infringed, valid, and owned by 10x Genomics. The judge’s finding regarding Patent No. 9,644,204 was not described as part of the affirmed violation findings.
  • The ITC issued an exclusion order prohibiting Bio-Rad from importing infringing microfluidic devices, components, and products containing them, including ddSEQ products.
  • The ITC also issued a cease-and-desist order preventing Bio-Rad from selling such imported products in the United States.
  • The orders do not prohibit certain microfluidic consumables imported for researchers with documented, ongoing research needs that cannot be met by an alternative product.

Outlook, risks, and unusual items

  • The Final Determination was subject to a 60-day presidential review period.
  • 10x Genomics expected Bio-Rad to appeal to the U.S. Court of Appeals for the Federal Circuit and expected the appeals to conclude in mid-2021. These are forward-looking statements and may not occur as anticipated.
  • Potential effects on 10x Genomics’ business and financial condition are not quantified in the filing.
  • The filing cautions that litigation outcomes, appeals, business conditions, and other risks could cause actual results to differ materially from forward-looking statements.
  • The disclosure was furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference into other filings, except where expressly stated.

Important facts for investors to verify

  • Whether the presidential review period resulted in modification, approval, or disapproval of the ITC remedial orders.
  • The status and ultimate outcome of Bio-Rad’s anticipated Federal Circuit appeal.
  • The practical scope and enforcement of the exclusion and cease-and-desist orders, including treatment of exempted research consumables.
  • Any subsequent disclosure quantifying the commercial or financial impact on 10x Genomics, Bio-Rad, or the affected products.
  • Updates in later SEC filings regarding patent litigation, contingencies, and related risks.